摘要
Abstract
Objective:Thalidomide combined with VAD regimen of multiple myeloma ( MM) clinical efficacy and adverse reactions were evaluated .Methods 42 patients with newly diagnosed MM patients , using a random number table is divided into two sets of line com-pared treatment , The control group VAD regimen , thalidomide in the treatment group on the VAD regimen the basis of the control group , Starting dose of thalidomide 100mg.d-1, divided into morning and evening oral , Weekly increments 50mg, maximum dose 300mg.d-1.Two groups patients were treated for three course of treatment .Results:The treatment group of 22 patients, partial remission in 12 ca-ses, The total efficiency of 77.3%;The control group of 20 patients, partial remission in 4 cases, The total efficiency of 55%, Effective rates in the two groups had significant difference (P<0.05);IntheM-protein,bonemarrow plasma cells and β2-microglobulin(β2-MG) and other indicators , Two groups were significantly decreased compared with those before treatment , treatment of various indexes of the difference between groups was significant (P<0.05).Conclusion:In contrast to the use of VAD regimen , thalidomide combined with VAD regimen in the treatment of multiple myeloma clinical curative effect is more obvious , Having few side effects ,tolerance is good wait for an advantage , it is worthy of clinical application .关键词
多发性骨髓瘤( MM)/沙利度胺/VAD方案/不良反应/临床疗效Key words
Multiple myeloma/Thalidomide/VAD regimen/Adverse reactions/Clinical efficacy分类
医药卫生
